Pharmacogenetic Approach to Anti-platelet Therapy for the Treatment of ST-segment Elevation Myocardial Infarction (STEMI)

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 102 participants.

Also called NCT01452139

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 102 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01452139
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Canada (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01452139. Randomized; single masking; primary purpose treatment. Start 2011-09 (registry gives no type); primary completion 2012-09 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Pharmacogenetic Approach to Anti-platelet Therapy for the Treatment of ST-segment Elevation Myocardial Infarction (STEMI)
Acronym
RAPID STEMI
Condition
STEMI
Intervention (Genetic)
Point-of-Care Genetic Testing
Intervention (Drug)
Prasugrel
Lead sponsor
Ottawa Heart Institute Research Corporation (class: other)
Collaborator
Spartan Bioscience Inc. (class: industry)

Record details

Record id
cardio:ct-nct01452139
Content hash
013bd568bc2f023ed06e5b2739d6291206a1b741a1fa93b218e3bb5978f16cd0